NCT06590519 Date Seed Extract Effectiveness in Controlling Diabetes and Cardiovascular Risk in T2DM
| NCT ID | NCT06590519 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universiti Putra Malaysia |
| Condition | Type 2 Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2024-07-01 with a primary completion date of 2025-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Globally, chronic noncommunicable diseases rank as the leading cause of morbidity and mortality. Diabetes is reaching high epidemic proportions across the globe. The prevalence of diabetes is increasing in Saudi Arabia, with diabetes affecting 14.1% of the population across all age groups and 28% of those over the age of 30. Date seed intake is one of the best-studied patterns. Previous studies findinds showed that the phenolic compounds in date seeds have blood sugar-lowering properties. There is a lack of data on how date seed diets may affect glycaemia control and cardiovascular risk among Saudi Arabian patients with T2DM. Therefore, randomised controlled trials (RCTs) will be conducted to assess the effects of date seeds on glycaemic control and cardiovascular risk among diabetes patients.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years old and above. * Diagnosis of Type 2 diabetes. * Receiving and monitoring diabetes care from diabetes center. * With stable HbA1c less than 10% (no episode of hypoglycaemia, no hospitalisation, no change in type or dosage of medication use for at least 6 months). Exclusion Criteria: * Pregnant or lactating women. * Diagnosis of cardiac failure or/and severe renal disease, with physical or mental disability, neurological or cognitive impairment. * Participant with severely impaired vision, hearing, or speech. * Participants who have known allergy to dates products.
Contact & Investigator
Zuriati Ibrahim, PhD
PRINCIPAL INVESTIGATOR
UniversitI Putra Malaysia (UPM), 43400 Serdang, Selangor, Malaysia
Frequently Asked Questions
Who can join the NCT06590519 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Type 2 Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06590519 currently recruiting?
Yes, NCT06590519 is actively recruiting participants. Contact the research team at maaaldaham8@gmail.com for enrollment information.
Where is the NCT06590519 trial being conducted?
This trial is being conducted at Serdang, Malaysia.
Who is sponsoring the NCT06590519 clinical trial?
NCT06590519 is sponsored by Universiti Putra Malaysia. The principal investigator is Zuriati Ibrahim, PhD at UniversitI Putra Malaysia (UPM), 43400 Serdang, Selangor, Malaysia. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.